Marleen van de Sande

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

Désirée van der Heijde, James Cheng‐Chung Wei, Maxime Dougados et al. · The Lancet · 2018 · 359 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +14

Interleukin‐17–positive mast cells contribute to synovial inflammation in spondylarthritis

Troy Noordenbos, Nataliya Yeremenko, Ioana Gofita et al. · Arthritis & Rheumatism · 2011 · 268 citations

Medicine, Immunology, Pathology +16

Magnetic Resonance Imaging of the Sacroiliac Joints Indicating Sacroiliitis According to the Assessment of SpondyloArthritis international Society Definition in Healthy Individuals, Runners, and Women With Postpartum Back Pain

J. de Winter, Manouk de Hooge, Marleen van de Sande et al. · Arthritis & Rheumatology · 2018 · 239 citations · Full text

Medicine, Radiology, Orthopedics +16

Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo‐Controlled Phase III Study

Atul Deodhar, Ricardo Blanco, Eva Dokoupilová et al. · Arthritis & Rheumatology · 2020 · 160 citations · Full text

Medicine, Pharmacotherapy, Musculoskeletal Medicine +15

ASAS consensus definition of early axial spondyloarthritis

Victoria Navarro‐Compán, Diego Benavent, Dafne Capelusnik et al. · Annals of the Rheumatic Diseases · 2023 · 69 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +6